UK markets closed

Laboratory Corporation of America Holdings (0JSY.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
232.71+10.69 (+4.81%)
At close: 04:25PM BST
Full screen
Previous close222.02
Bid0.00 x 0
Ask0.00 x 0
Day's range232.71 - 232.71
52-week range232.71 - 232.71
Avg. volumeN/A
Market cap23.076B
Beta (5Y monthly)1.04
PE ratio (TTM)10.68
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Tigerlily Foundation and Labcorp Collaborate to Increase Clinical Trial Diversity for Women of Color

    BURLINGTON, N.C. & ALDIE, Va., June 24, 2022--Labcorp, a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions. Labcorp has signed Tigerlily’s #InclusionPledge for Black Women, joining other healthcare and life sciences companies in committing to eradicate barriers for women of color in acces

  • Business Wire

    Labcorp Enhances Clinical Trial and Drug Development Capabilities Through Real World Data Collaboration With HealthVerity

    BURLINGTON, N.C., June 21, 2022--Labcorp® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs.

  • Business Wire

    Labcorp Expands Access to Comprehensive Genomic Testing Through New Lung Cancer Program

    BURLINGTON, N.C., June 02, 2022--Labcorp (NYSE: LH), a leading global life sciences company, understands the important and growing role of precision medicine and is working to ensure more people have access to targeted and personalized treatments. As part of this effort, the company is announcing a new sponsored testing program aimed at helping advanced non-small cell lung (NSCLC) cancer patients and their physicians make informed treatment and care management decisions through comprehensive gen